In a cardiac patient who develops vitreous hemorrhage, should antiplatelet therapy be stopped, and if so, how long should it be held?

Management of Antiplatelet Therapy in Cardiac Patients with Vitreous Hemorrhage

In cardiac patients who develop spontaneous vitreous hemorrhage while on antiplatelet therapy, aspirin should generally be continued, while P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) should be temporarily stopped for 5-7 days if vitrectomy is required, with resumption within 24-72 hours post-operatively based on bleeding risk.

Key Decision Points

For Aspirin Monotherapy

• Continue aspirin in most cases of vitreous hemorrhage 1
• Recent meta-analysis shows aspirin continuation does not significantly increase vitreous hemorrhage risk (RR 1.55,95% CI: 0.73–3.29) or other hemorrhagic complications during vitreoretinal surgery 1
• The thrombotic risk of stopping aspirin outweighs the minimal bleeding risk in most scenarios 2

For Dual Antiplatelet Therapy (DAPT)

This is where management becomes more nuanced and depends critically on timing of coronary stent placement:

If Stent Placed <6 Weeks Ago:

• Continue both aspirin and P2Y12 inhibitor if at all possible 3, 4
• Vitrectomy should ideally be postponed beyond 1 month post-stent 4
• If surgery cannot be delayed, perform in a facility with 24/7 catheterization lab availability 4
• Consider bridging with IV cangrelor or tirofiban (off-label) only in exceptional circumstances with ICU monitoring 4

If Stent Placed 6 Weeks to 3 Months Ago:

• Continue aspirin, consider stopping P2Y12 inhibitor 3
• Stop clopidogrel 5-7 days pre-operatively 3, 4
• Stop prasugrel 7 days pre-operatively 3
• Stop ticagrelor 3-5 days pre-operatively 3
• Resume P2Y12 inhibitor within 24-72 hours post-operatively 4

If Stent Placed >3 Months Ago:

• Continue aspirin, stop P2Y12 inhibitor 3
• Same discontinuation timeline as above
• Resume within 24-72 hours post-operatively 4

For Patients Without Recent Stents

• Continue aspirin 1
• Stop P2Y12 inhibitor 5-7 days before vitrectomy if planned 3
• Resume within 24-72 hours after surgery 4

Critical Risk Factors to Assess

The decision must weigh:

1. Cardiac thrombotic risk:

   • Recent myocardial infarction (<6 months)
   • Type of stent (drug-eluting vs bare-metal)
   • Stent location (dominant coronary artery)
   • Number and length of stents
   • History of stent thrombosis

2. Bleeding risk factors:

   • Dual vs triple antithrombotic therapy significantly increases vitreous hemorrhage risk 5
   • Younger age paradoxically increases post-operative vitreous hemorrhage risk 6
   • Presence of proliferative diabetic retinopathy 6
   • Anticoagulation combined with antiplatelet therapy carries highest risk 5

Important Caveats

Evidence Limitations

• Most vitreoretinal surgery studies show no substantial increase in bleeding with aspirin continuation 2, 7, 1
• However, one study found antiplatelet use associated with higher post-operative vitreous hemorrhage rates (20% vs 9.6%), though this lost statistical significance in multivariate analysis 2
• Dual antiplatelet therapy increases vitreous hemorrhage risk substantially (HR 5.02) compared to warfarin monotherapy 5

Anticoagulation Considerations

If patient is also on warfarin or DOACs:

• INR <3 appears relatively safe for vitreoretinal surgery 7
• Anticoagulants show higher association with first-day post-operative hemorrhage 2
• Triple therapy (warfarin + dual antiplatelet) carries highest risk (HR 6.12) and should be avoided when possible 5

Coordination Requirements

• Mandatory cardiology consultation for patients with recent stents or high thrombotic risk 4
• Document discussion and decision-making in medical record 4
• Ensure 24/7 catheterization lab availability if operating within 1 month of stent placement 4

Practical Algorithm

1. Identify cardiac indication: Recent ACS/stent vs stable CAD vs stroke prevention
2. Determine stent timing: <6 weeks, 6 weeks-3 months, >3 months, or no stent
3. Assess urgency: Can vitrectomy be safely delayed?
4. If urgent and recent stent: Continue both agents, operate with cath lab backup
5. If semi-urgent and stent >6 weeks: Continue aspirin, stop P2Y12 inhibitor 5-7 days pre-op
6. If no recent stent: Continue aspirin, stop P2Y12 inhibitor if needed
7. Resume P2Y12 inhibitor within 24-72 hours post-operatively unless ongoing bleeding 4

The evidence strongly supports that aspirin continuation is safe and should be the default approach, while P2Y12 inhibitor management requires individualized risk stratification based primarily on stent timing 3, 4, 1.